CERS Cerus Corporation
USHealthcareAs of 2026-07-10 16:00
Why CERS matters now
Cerus Corporation (CERS) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.12 with -0.95% on the session and $625.2M in market capitalization; recent performance reads 1-month +0.00% and YTD +31.07%.
The latest financial table shown here is Q1 2026, with revenue of $59.9M, net income of $-1.6M, and EPS of $-0.01. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.2%.
The latest indexable market news headline is "Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.00; recent insider activity includes BJERKHOLT ERIC filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.76
P/S
2.43
EV/EBITDA
513.03
DCF Value
$2.90
FCF Yield
-0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.3%
Operating Margin
-7.9%
Net Margin
-4.3%
ROE
-15.4%
ROA
-4.3%
ROIC
-10.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $59.9M | $-1.6M | $-0.01 |
| Q4 2025 | $57.8M | $-2.2M | $-0.01 |
| FY 2025 | $206.1M | $-15.6M | $-0.08 |
| Q3 2025 | $52.7M | $-19.0K | $-0.00 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.00
Target (Median)
$4.00
Target Range
$4.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.77
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.